KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $316.2 million.

  • CRISPR Therapeutics AG's Non-Current Assets rose 127.37% to $316.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 521.74%. This contributed to the annual value of $304.9 million for FY2024, which is 516.06% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Non-Current Assets of $316.2 million as of Q3 2025, which was up 127.37% from $296.0 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Non-Current Assets peaked at $420.7 million during Q3 2022, and registered a low of $125.6 million during Q1 2021.
  • Moreover, its 5-year median value for Non-Current Assets was $321.5 million (2023), whereas its average is $318.5 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Non-Current Assets soared by 24428.65% in 2021, and later tumbled by 2244.34% in 2023.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Non-Current Assets stood at $334.4 million in 2021, then increased by 16.65% to $390.0 million in 2022, then dropped by 17.57% to $321.5 million in 2023, then decreased by 5.16% to $304.9 million in 2024, then increased by 3.71% to $316.2 million in 2025.
  • Its Non-Current Assets was $316.2 million in Q3 2025, compared to $296.0 million in Q2 2025 and $298.5 million in Q1 2025.